Search results for "TUMOR"

showing 10 items of 6365 documents

Potential Molecular Players of the Tumor Microenvironment in Extracranial Pediatric Solid Tumors

2020

Pediatric cancers are rare malignancies worldwide and represent around 1% of all new cancer diagnoses [...]

0301 basic medicineCancer ResearchTumor microenvironmentbusiness.industryCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-28203 medical and health sciences030104 developmental biology0302 clinical medicineEditorialn/aOncology030220 oncology & carcinogenesisCancer researchMedicinebusinessCancers
researchProduct

Abstract LB-130: Combinatorial treatment with intratumoral cytokine mRNAs results in high frequency of tumor rejection and development of anti-tumor …

2018

Abstract Cancer immunotherapy localized to the tumor microenvironment holds great potential to promote innate and adaptive immune responses against tumors, while avoiding toxicities related to systemic administration of immuno-modulatory therapeutics. Current strategies for tumor-targeted, gene-based delivery of immune therapies face limitations in the clinic due to suboptimal target expression, anti-vector immunity, potential for unwanted genomic rearrangements and other off target effects. We developed a highly potent synthetic mRNA-based platform for in vivo transfection and sustained intratumoral expression of immuno-modulatory molecules that is capable of inducing immunity to tumor spe…

0301 basic medicineCancer ResearchTumor microenvironmentbusiness.industrymedicine.medical_treatmentAbscopal effectCancerImmunotherapymedicine.diseaseOncolytic virus03 medical and health sciences030104 developmental biology0302 clinical medicineCytokineImmune systemOncologyCancer immunotherapy030220 oncology & carcinogenesisCancer researchmedicinebusinessCancer Research
researchProduct

Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling

2017

The pathogenesis of chronic lymphocytic leukemia (CLL) has been linked to constitutive NF-κB activation but the underlying mechanisms are poorly understood. Here we show that alternative splicing of the negative regulator of NF-κB and tumor suppressor gene CYLD regulates the pool of CD5+ B cells through sustained canonical NF-κB signaling. Reinforced canonical NF-κB activity leads to the development of B1 cell-associated tumor formation in aging mice by promoting survival and proliferation of CD5+ B cells, highly reminiscent of human B-CLL. We show that a substantial number of CLL patient samples express sCYLD, strongly implicating a role for it in human B-CLL. We propose that our new CLL-l…

0301 basic medicineCancer ResearchTumor suppressor geneCell SurvivalRNA SplicingChronic lymphocytic leukemia2720 Hematology610 Medicine & healthBiologyCD5 Antigenslaw.inventionPathogenesisMice03 medical and health sciencesimmune system diseaseslawhemic and lymphatic diseasesmedicineAnimalsHumans10239 Institute of Laboratory Animal Science1306 Cancer ResearchGenes Tumor SuppressorGeneCell ProliferationB-LymphocytesAlternative splicingNF-kappa BUbiquitinationHematologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellDeubiquitinating Enzyme CYLDLeukemia030104 developmental biologyOncologyImmunologyCancer research570 Life sciences; biologySuppressor2730 OncologyCD5Signal TransductionLeukemia
researchProduct

Inhibition of colon cancer growth by docosahexaenoic acid involves autocrine production of TNFα

2016

IF 7.932; International audience; The omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) has anti-inflammatory and anti-cancer properties. Among pro-inflammatory mediators, tumor necrosis factor a (TNF alpha) plays a paradoxical role in cancer biology with induction of cancer cell death or survival depending on the cellular context. The objective of the study was to evaluate the role of TNFa in DHA-mediated tumor growth inhibition and colon cancer cell death. The treatment of human colorectal cancer cells, HCT-116 and HCT-8 cells, with DHA triggered apoptosis in autocrine TNF alpha-dependent manner. We demonstrated that DHA-induced increased content of TNF alpha mRNA occurred thr…

0301 basic medicineCancer ResearchTumoricidal ActionApoptosis[ SDV.CAN ] Life Sciences [q-bio]/CancerMice[ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human geneticsForkhead Box Protein O3Cell cycle3. Good healthCell biologyGene Expression Regulation NeoplasticAutocrine CommunicationColonic NeoplasmsTumor-Necrosis-FactorTumor necrosis factor alphaProgrammed cell deathDocosahexaenoic AcidsHuman Colorectal-CancerGene-Expression[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiology03 medical and health sciencesGrowth factor receptorLipid-MetabolismGeneticsmedicineAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyCell-DeathPolyunsaturated Fatty-AcidsAutocrine signallingMolecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyActivated Protein-KinaseTumor Necrosis Factor-alpha[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyInduced ApoptosisCancerHCT116 Cellsmedicine.diseaseXenograft Model Antitumor AssaysMicroRNAs030104 developmental biology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsApoptosisCancer cellCancer researchPrevents Breast-Cancer
researchProduct

Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors.

2018

Due to an increased understanding of molecular biology and the genomics of cancer, new and potent agents have been approved by the Food and Drug Administration (FDA) to fight this disease. However, all of these drugs cause severe side effects and resistance inevitably develops, re-activating tumor growth and dissemination. For this reason, patients turn to natural compounds as alternative or complementary treatment options, since it has been found that natural plant products may block, inhibit, or reverse cancer development. The present review focusses on the role of the natural compound sulforaphane (SFN) as an anti-tumor agent in urologic cancer. SFN is a natural compound found in crucife…

0301 basic medicineCancer ResearchUrologic NeoplasmsApoptosisDisease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoIsothiocyanatesCell Line TumorHDAC inhibitorMedicineAnticarcinogenic AgentsHumansEpigeneticsMode of actionBiological ProductsMolecular Structurebusiness.industryCruciferous vegetablesCancermedicine.diseaseHistone Deacetylase Inhibitors030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisSulfoxidesBrassicaceaeCancer researchbusinessSulforaphaneCancer letters
researchProduct

Editorial: Cell Stress, Metabolic Reprogramming, and Cancer

2018

0301 basic medicineCancer Researchantioxidant responseAntioxidant response; Ataxia-telangiectasia mutated; Cancer; Epithelial-to-mesenchymal transition; Glutamine; Hypoxia-inducible factor 1 alpha; L-lactate; Mitochondria; Oncology; Cancer ResearchMetabolic reprogrammingMitochondrionBiologylcsh:RC254-28203 medical and health sciencesHypoxia-Inducible Factor 1-AlphamedicinecancerGlycolysisEpithelial–mesenchymal transitionataxia-telangiectasia mutatedCancerL-lactatemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensGlutaminemitochondriaCell stress030104 developmental biologyEditorialOncologyCancer researchglutaminehypoxia-inducible factor 1 alphaepithelial-to-mesenchymal transition
researchProduct

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide

2018

Rationale: The activity of the transcription factor, hypoxia-inducible factor (HIF)-1?, is a common driver of a number of the pathways involved in the aggressiveness of glioblastomas (GBMs), and it has been suggested that the reduction in this activity observed, soon after the administration of temozolomide (TMZ), can be a biomarker of an early response in GBM models. As HIF-1? is a tightly regulated protein, studying the processes involved in its downregulation could shed new light on the mechanisms underlying GBM sensitivity or resistance to TMZ. Methods: The effect of HIF-1? silencing on cell responsiveness to TMZ was assessed in four genetically different human GBM cell lines by evaluat…

0301 basic medicineCancer Researchapoptosis; chaperone-mediated autophagy activity; hypoxia-inducible factor-1? silencing; temozolomide responsiveness; theranostic biomarkerBiologylcsh:RC254-28203 medical and health scienceshypoxia-inducible factor-1α silencing0302 clinical medicineGliomamedicineGene silencingViability assayTranscription factorOriginal Researchchaperone-mediated autophagy activityTemozolomideAutophagyapoptosismedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstheranostic biomarker030104 developmental biologyHypoxia-inducible factorsOncologyApoptosis030220 oncology & carcinogenesisCancer researchtemozolomide responsivenessmedicine.drugFrontiers in Oncology
researchProduct

Targeting Immune Modulators in Glioma While Avoiding Autoimmune Conditions

2021

Simple Summary Glioblastoma multiforme is a futile disease usually leading to the patient’s death within one year post-diagnosis; therefore, novel treatment options are desperately needed. In this regard, activation of the inert immune system has moved into focus in recent years. Malignant brain tumors, as well as autoimmune diseases, elicit aberrant immune responses. In this way, glioma escapes the host’s immune system and, thus, activation of the immune response in order to reduce tumor tolerance can serve as an alternative treatment option. Immune checkpoint modulators in combination with traditional therapies have gained attention in both glioma and autoimmune diseases. In this review, …

0301 basic medicineCancer Researchautoimmune disease ; immune checkpoints ; immunotherapy ; clinical trials ; Gliom ; gliomamedicine.medical_treatmentautoimmune diseaseContext (language use)Review03 medical and health sciences0302 clinical medicineImmune systemgliomaGliomamedicineRC254-282Autoimmune diseaseclinical trialsTumor microenvironmentbusiness.industryMultiple sclerosisNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunosuppressionImmunotherapybiochemical phenomena metabolism and nutritionimmune checkpointsmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchimmunotherapybusinessCancers
researchProduct

Impact des facteurs nutritionnels pendant et après cancer

2021

Nutritional factors (diet, weight, alcohol, physical activity) are identified as factors having an impact on the onset of several cancer sites. Less abundant scientific data also underline their impact on the tumor progression. A review of the scientific literature was carried out by a group of experts established by the French National Cancer Institute (INCa) to better document the influence of nutritional factors during and after cancer on outcomes such as overall mortality, cancer specific mortality, recurrence, second primary cancers and quality of life. This analysis of the literature completes messages of reduction of alcohol consumption, prevention of undernutrition or excess weight …

0301 basic medicineCancer Researchbusiness.industryCancerHematologyGeneral MedicineScientific literaturemedicine.disease03 medical and health sciencesMalnutrition030104 developmental biology0302 clinical medicineQuality of life (healthcare)OncologyTumor progression030220 oncology & carcinogenesisEnvironmental healthmedicineRadiology Nuclear Medicine and imagingbusinessCancer specific mortalitySedentary lifestyleTertiary PreventionBulletin du Cancer
researchProduct

An International Proficiency Study with the Tumor Marker CA 125

1990

A strict and adequate quality assurance program is the only real guarantee of the reliability of laboratory test results. Such proficiency testing was carried out for the CA 125 test system in five university laboratories over a period of three years (1984 - 1987) using five different reference materials (BIOREF, FRG). A concentration-dependent performance profile could thus be established evaluating a total of 301 assays. Intra-assay precision of the test ranged between 4.8 and 11.5%, and interassay precision between 13.6 and 19.1%. Laboratory specific average values of the individual reference materials ranged between 26 and 32 U/ml for reference 1, 51 and 59 U/ml for reference 2, 109 an…

0301 basic medicineCancer Researchbusiness.industryClinical BiochemistrySignificant differencePathology and Forensic Medicine03 medical and health sciencesLaboratory test030104 developmental biology0302 clinical medicineAnimal scienceOncology030220 oncology & carcinogenesisProficiency testingbusinessQuality assuranceReference standardsTumor markerMathematicsThe International Journal of Biological Markers
researchProduct